(S050) Stereotactic Radiosurgery in the Setting of Immune Checkpoint Blockade Results in Improved Intracranial Control Compared With Whole-Brain Irradiation for Greater Than Three Melanoma Brain Metastases
SRS, in the setting of systemic immunotherapy, may provide improved intracranial control compared with WBRT in patients with ≥ 3 melanoma brain metastases. Future prospective studies may expand the utility of SRS and spare selective patients with large intracranial disease burdens from toxicities associated with WBRT.
Penny Fang, MD, Wen Jiang, MD, Betty Y. Kim, MD, PhD, Isabella C. Glitza, MD, PhD, Anita Mahajan, MD, Michael A. Davies, MD, PhD, Franco DeMonte, MD, Patrick Hwu, MD, Erik P. Sulman, MD, PhD, Paul D. Brown, MD, Jing Li, MD, PhD; UT MD Anderson Cancer Center; Mayo Clinic Jacksonville
BACKGROUND: Whole-brain radiation therapy (WBRT) is a commonly accepted treatment of choice for patients with ≥ 3 brain metastases, because of concern about intracranial microscopic disease. With increased use of immune checkpoint inhibitors in metastatic cancers, several studies have suggested that improved intracranial control by stereotactic radiosurgery (SRS) is also achievable. We investigated whether SRS, combined with cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) blockade, can result in superior intracranial control compared with WBRT alone in patients with ≥ 3 melanoma brain metastases.
METHODS: From 2007 to 2014, patients diagnosed with metastatic melanoma who received ipilimumab (Ipi) and SRS for new brain metastases after the initiation of immunotherapy were identified. Only patients treated with ≥ 3 lesions were included. A matching cohort of patients who received WBRT without prior immunotherapies was identified and compared.
RESULTS: A total of 59 patients with metastatic melanoma were included in the study; 22 were treated with SRS + Ipi and 37 with WBRT alone. Patients received at least two doses prior to SRS. The majority of the patients (86.4%) received SRS within 5 months from the last Ipi treatment. The median number of treated brain metastases was 6 for SRS + Ipi (range: 4–22) and 7 (range: 4–25) for WBRT. Patients treated with SRS + Ipi had significantly improved intracranial control compared with WBRT alone, with a 12-month intracranial progression-free rate of 26% vs 13% (P = .028). There was a trend toward improved overall survival (OS) for patients who received SRS + Ipi (median: 9.61 mo vs 4.47 mo; P = .09). The improved intracranial control for SRS + Ipi remained significant on multivariate analysis.
CONCLUSIONS: SRS, in the setting of systemic immunotherapy, may provide improved intracranial control compared with WBRT in patients with ≥ 3 melanoma brain metastases. Future prospective studies may expand the utility of SRS and spare selective patients with large intracranial disease burdens from toxicities associated with WBRT.
Proceedings of the 98th Annual Meeting of the American Radium Society -americanradiumsociety.org
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
